Phase Forward CFO Chris Menard to Present at 2009 MIT Sloan CFO Summit

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that company Senior Vice President and CFO Chris Menard will be participating in the 2009 MIT Sloan CFO Summit as a featured panelist. Menard will join more than 500 distinguished financial executives from around the world and leading MIT Sloan faculty at the Summit, which will take place Thursday, November 19, 7:30 a.m. – 6:00 p.m. at the Boston Marriott Newton in Newton, Mass.

One of more than 30 presenters from a wide range of industries, Menard will participate in an 11 a.m. panel focused on mergers and acquisitions in today’s market.

“The MIT Sloan CFO Summit is a high-caliber forum where leading executives can share best practices with their peers,” said Menard. “Since Phase Forward has completed six acquisitions in recent years, I’m happy to discuss our experience in developing the strategy and in executing these deals.”

This year’s theme, “Thriving in a New World Order” will drive discussions on the future of finance, accounting and strategic business initiatives. The Summit also offers attendees the unique opportunity to hear MIT Sloan academicians and successful business leaders explore these critical issues together.

About the MIT Sloan CFO Summit

The MIT Sloan CFO Summit is the nation’s premier CFO event. Each year, the event offers a day of cutting-edge programming that addresses the changing role of the CFO. The event is rich with opportunities for practical education and peer networking in a time-efficient format. The summit is part of the CXO Series produced by the MIT Sloan School of Management, one of the world’s leading academic sources of innovation in management theory and practice, and the MIT Sloan Alumni Club of Boston. The annual events are organized 100 percent by alumni volunteers. By promoting the MIT philosophy of “mens et manus,” or “mind and hand,” they are able to bring together the academic research from MIT Sloan with today’s corporate financial leaders to foster debate and provide informative discourse.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024